“I have been extremely satisfied with CBT’s services, having been a client since 2013.
Through this partnership, we have had three successful pre-IND meetings with the FDA that have led to two IND filings, with a third in the works. The recommendations provided by CBT were cost-effective and more importantly completely accepted by the Agency without question. They are clearly an experienced group, provide timely responses, and have been a pleasure to work with.”
Jonathan Sorger, VP of Research, Intuitive Surgical
"CBT has been a key partner in our pre- and clinical development. They delivered our entire IND-enabling toxicology package (GLP toxicology in 2 species) on schedule and within budget. They developed extremely complex analytical assays for our lead compound and its metabolites and now support PK part of our clinical trials in Australia and USA. I was very impressed with how quick the studies were initiated, progressed on schedule and always with high levels of quality control. In addition, along the way, we have received a lot of great advice on how to run our studies in a most efficient and cost-effective manner. CBT has become a part of our team and our go-to preclinical and analytical CRO."
Ilya Rachman, MD, PhD, MBA
CEO, Immix Biopharma, Inc